Regenerex Pharma, Inc.

RGPX SEC CIK 1357878
Follow Regenerex Pharma Weekly email: filings, results, news

Financials

Reported figures only · latest: Q3 2025 USD · US GAAP
Net income −$814K −53.7% vs same quarter last year
EPS, diluted -
Operating cash flow −$250.2K −57.6% vs same quarter last year
Operating income −$786.7K −204.5% vs same quarter last year
Net income by quarter
−$272.6K
−$529.6K
−$314.5K
$16.2K
−$663.6K
−$814K
Q2 24 Q3 24 Q4 24 Q4 25 Q2 25 Q3 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
−$4M−$2M$0$2MFY09FY11FY13FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$2.5M
FY24−$3.5M
FY23−$137.3K
FY22−$195.6K
FY21−$353.8K
FY20$111.6K
FY19−$93.6K
FY18−$49.7K
FY17−$2.6K
FY14$859.8K
FY13−$995.5K
FY12−$659.7K
FY11−$212.1K
FY10−$27.4K
FY09−$6.4K

News

No stories filed under Regenerex Pharma yet - coverage appears here as the news feed clusters it.